
Carlsmed rose 40.9% from $12.31 to $17.35, ahead of the S&P 500's +11.2%. Its worst day was Dec 4 (−15.2%), and its low came Apr 29 at $8.83.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Carlsmed shares fell 15.2%, while the S&P 500 rose 0.1%.
−15.2%, the year's worst day · S&P 500 +0.1%
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024CARLSBAD, Calif., Jan.
+13.8% · S&P 500 +0.2%
EPS of $-0.32 beat the $-0.43 estimate on $15.2M revenue (est. $14.9M); FY revenue guidance of $70.0M–$75.0M against the $69.5M consensus.
+15.9% · S&P 500 −0.6%
EPS of $-0.32 beat the $-0.40 estimate on $16.1M revenue (est. $14.9M); FY revenue guidance of $72.0M–$77.0M against the $72.5M consensus.
+10.3% · S&P 500 +1.4%
Carlsmed shares rose 12.8%, while the S&P 500 fell 0.1%.
+12.8% · S&P 500 −0.1%
EPS of $-0.39 missed the $-0.38 estimate on $18.9M revenue (est. $18.1M); FY revenue guidance of $74.0M–$78.0M against the $75.0M consensus.
+1.0% · S&P 500 −0.2%
EPS of $-0.34 beat the $-0.39 estimate on $21.6M revenue (est. $19.2M); FY revenue guidance of $78.0M–$80.0M against the $76.7M consensus.
+26.4%, the year's best day · S&P 500 +1.3%
Where it ended: a close of $17.35 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.36, revenue est. $23.9M).
Nothing in the past 12 months.
All CARL dividend history